CorMedix (CRMD) Competitors $10.61 +0.07 (+0.66%) Closing price 04:00 PM EasternExtended Trading$10.60 -0.01 (-0.09%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRMD vs. LNTH, TLX, ADMA, AMRX, INDV, CNTA, APLS, XENE, GMTX, and RAREShould you be buying CorMedix stock or one of its competitors? The main competitors of CorMedix include Lantheus (LNTH), Telix Pharmaceuticals (TLX), ADMA Biologics (ADMA), AMNEAL PHARMACEUTICALS (AMRX), Indivior (INDV), Centessa Pharmaceuticals (CNTA), Apellis Pharmaceuticals (APLS), Xenon Pharmaceuticals (XENE), Gemini Therapeutics (GMTX), and Ultragenyx Pharmaceutical (RARE). These companies are all part of the "pharmaceutical products" industry. CorMedix vs. Its Competitors Lantheus Telix Pharmaceuticals ADMA Biologics AMNEAL PHARMACEUTICALS Indivior Centessa Pharmaceuticals Apellis Pharmaceuticals Xenon Pharmaceuticals Gemini Therapeutics Ultragenyx Pharmaceutical Lantheus (NASDAQ:LNTH) and CorMedix (NASDAQ:CRMD) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations. Does the media refer more to LNTH or CRMD? In the previous week, Lantheus had 37 more articles in the media than CorMedix. MarketBeat recorded 42 mentions for Lantheus and 5 mentions for CorMedix. Lantheus' average media sentiment score of 0.02 beat CorMedix's score of -0.16 indicating that Lantheus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 2 Very Positive mention(s) 3 Positive mention(s) 26 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Neutral CorMedix 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility and risk, LNTH or CRMD? Lantheus has a beta of 0.09, meaning that its stock price is 91% less volatile than the S&P 500. Comparatively, CorMedix has a beta of 1.85, meaning that its stock price is 85% more volatile than the S&P 500. Do analysts recommend LNTH or CRMD? Lantheus currently has a consensus target price of $74.50, suggesting a potential upside of 31.81%. CorMedix has a consensus target price of $18.00, suggesting a potential upside of 69.65%. Given CorMedix's stronger consensus rating and higher probable upside, analysts clearly believe CorMedix is more favorable than Lantheus.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lantheus 0 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50CorMedix 0 Sell rating(s) 4 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.70 Is LNTH or CRMD more profitable? CorMedix has a net margin of 42.11% compared to Lantheus' net margin of 17.82%. CorMedix's return on equity of 42.73% beat Lantheus' return on equity.Company Net Margins Return on Equity Return on Assets Lantheus17.82% 34.06% 19.10% CorMedix 42.11%42.73%34.19% Which has better earnings and valuation, LNTH or CRMD? Lantheus has higher revenue and earnings than CorMedix. CorMedix is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLantheus$1.53B2.51$312.44M$3.7615.03CorMedix$43.47M19.05-$17.93M$0.7514.15 Do insiders & institutionals have more ownership in LNTH or CRMD? 99.1% of Lantheus shares are owned by institutional investors. Comparatively, 34.2% of CorMedix shares are owned by institutional investors. 1.5% of Lantheus shares are owned by insiders. Comparatively, 5.3% of CorMedix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. SummaryCorMedix beats Lantheus on 10 of the 17 factors compared between the two stocks. Get CorMedix News Delivered to You Automatically Sign up to receive the latest news and ratings for CRMD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CRMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRMD vs. The Competition Export to ExcelMetricCorMedixMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$822.74M$3.38B$6.11B$10.47BDividend YieldN/A2.29%5.73%4.77%P/E Ratio14.1522.7785.3627.36Price / Sales19.05483.07607.44135.43Price / CashN/A46.7037.4661.86Price / Book7.5810.5512.426.81Net Income-$17.93M-$52.58M$3.32B$276.80M7 Day Performance-5.86%1.09%1.01%0.27%1 Month Performance-16.13%16.09%10.75%8.31%1 Year Performance5.15%18.41%76.20%35.60% CorMedix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRMDCorMedix2.84 of 5 stars$10.61+0.7%$18.00+69.7%+4.8%$822.74M$43.47M14.1530LNTHLantheus4.562 of 5 stars$52.70-2.1%$85.50+62.2%-50.3%$3.58B$1.53B14.02700Trending NewsAnalyst RevisionTLXTelix Pharmaceuticals4.2366 of 5 stars$10.18-1.0%$21.00+106.3%N/A$3.45B$516.72M0.00N/ATrending NewsAnalyst RevisionGap UpADMAADMA Biologics3.5043 of 5 stars$14.07-4.0%$27.67+96.6%-8.7%$3.36B$474.17M16.36530News CoverageAMRXAMNEAL PHARMACEUTICALS3.8611 of 5 stars$10.55+1.5%$12.00+13.7%+12.2%$3.31B$2.79B1,056.068,100INDVIndivior3.3795 of 5 stars$22.73-1.9%$22.00-3.2%+210.6%$3.13B$1.17B36.661,051News CoverageCNTACentessa Pharmaceuticals2.848 of 5 stars$23.00-1.0%$32.38+40.8%+34.5%$3.08B$6.85M-12.85200APLSApellis Pharmaceuticals4.1952 of 5 stars$24.36+2.4%$33.29+36.7%-15.4%$3.08B$781.37M-13.38770News CoverageAnalyst ForecastAnalyst RevisionXENEXenon Pharmaceuticals2.686 of 5 stars$39.55-0.2%$53.30+34.8%-2.8%$3.05B$9.43M-11.14210Analyst ForecastGMTXGemini TherapeuticsN/A$67.78+2.9%N/A+50.7%$2.94BN/A-67.7830RAREUltragenyx Pharmaceutical4.4465 of 5 stars$30.19-3.3%$81.50+170.0%-43.6%$2.91B$560.23M-5.461,294News CoverageInsider TradeAnalyst Revision Related Companies and Tools Related Companies LNTH Alternatives TLX Alternatives ADMA Alternatives AMRX Alternatives INDV Alternatives CNTA Alternatives APLS Alternatives XENE Alternatives GMTX Alternatives RARE Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRMD) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CorMedix Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share CorMedix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
